Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas

Blood

Volumn 128, Issue 9, 2016, Pages 1206-1213

  Chong, Lauren C ^a,b   Twa, David D W ^a,c   Mottok, Anja ^a,c   Ben Neriah, Susana ^a   Woolcock, Bruce W ^a   Zhao, Yongjun ^d   Savage, Kerry J ^a   Marra, Marco A ^a,b,d   Scott, David W ^a   Gascoyne, Randy D ^a,c   Morin, Ryan D ^d,e   Mungall, Andrew J ^a,d   Steidl, Christian ^a,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CANADA'S MICHAEL SMITH GENOME SCIENCES CENTRE   (Canada)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 4 RECEPTOR; OLIGONUCLEOTIDE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROTEIN TYROSINE PHOSPHATASE 1B; CD274 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; B CELL LYMPHOMA; BASE PAIRING; BZRAP AS1 GENE; CHROMOSOME BREAKAGE; COCULTURE; ECTOPIC EXPRESSION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE DUPLICATION; GENE LOCUS; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; JURKAT CELL LINE; KIAA0226L GENE; LARGE CELL LYMPHOMA; MID1 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RCC1 GENE; T LYMPHOCYTE ACTIVATION; CASE REPORT; CHROMOSOME ABERRATION; FEMALE; GENETICS; HUMAN CHROMOSOME; IMMUNOLOGY; MALE; TUMOR CELL LINE;

ANTIGENS, CD274; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; FEMALE; GENETIC LOCI; HUMANS; LYMPHOMA, B-CELL; MALE; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN;

EID: 84987657278     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-683003     Document Type: Article

References (31)

1. Amarnath S, Mangus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011;3(111):111ra120.
2. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232-4244.
3. Gibson A, Ogese M, Sullivan A, et al. Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function. J Immunol. 2014;192(6):2611-2621.
4. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
5. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377-381.
6. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062-2065.
7. Twa DD, Mottok A, Chan FC, et al. Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol. 2015;236(2):136-141.
8. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611-1618.
9. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
10. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12(11):745-755.
11. Bouamar H, Abbas S, Lin AP, et al. A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood. 2013;122(5):726-733.
12. Corless CL, Spellman PT. Tackling formalin-fixed, paraffin-embedded tumor tissue with next-generation sequencing. Cancer Discov. 2012;2(1):23-24.
13. Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20(6):682-688.
14. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2(1):82-93.
15. Mottok A, Woolcock B, Chan FC, et al. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13(7):1418-1431.
16. Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869-881.
17. Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38(12):1715-1723.
18. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;JCO664482.
19. Chua YL, Ito Y, Pole JC, et al. The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene. 2009;28(46):4041-4052.
20. Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet. 2014;46(4):329-335.
21. Huisman C, Wisman GB, Kazemier HG, et al. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors. Mol Oncol. 2013;7(3):669-679.
22. Krenciute G, Liu S, Yucer N, et al. Nuclear BAG6-UBL4A-GET4 complex mediates DNA damage signaling and cell death. J Biol Chem. 2013;288(28):20547-20557.
23. Van Roosbroeck K, Ferreiro JF, Tousseyn T, et al. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. Genes Chromosomes Cancer. 2016;55(5):428-441.
24. Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.
25. Loeb GB, Khan AA, Canner D, et al. Transcriptome-wide miR-155 binding map reveals widespread noncanonical microRNA targeting. Mol Cell. 2012;48(5):760-770.
26. Ringnér M, Krogh M. Folding free energies of 5′-UTRs impact post-transcriptional regulation on a genomic scale in yeast. PLOS Comput Biol. 2005;1(7):e72.
27. Wang W, Li F, Mao Y, et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132(6):641-648.
28. Zhu J, Chen L, Zou L, et al. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014;75(4):348-353.
29. Wang SC, Lin CH, Li RN, et al. Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis. J Clin Immunol. 2007;27(6):563-567.
30. Lázár-Molnár E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC. Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci USA. 2008;105(30):10483-10488.
31. Carey CD, Gusenleitner D, Chapuy B, et al. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn. 2015;17(1):19-30.